CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
出版年份 2021 全文链接
标题
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2021-02-04
DOI
10.1111/ejh.13590
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cardiac complications of CDK4/6 inhibitors for breast cancer.
- (2020) Samip R. Master JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC).
- (2020) Ranju Kunwor et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer
- (2020) Hanny Al-Samkari et al. Journal of Thoracic Oncology
- Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients
- (2020) Orly Leiva et al. Cancers
- Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors
- (2020) Andrew Dunbar et al. BLOOD
- The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis
- (2019) Frits I. Mulder et al. HAEMATOLOGICA
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
- (2019) Lorenzo Gervaso et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma
- (2019) Ang Li et al. ANNALS OF HEMATOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
- (2018) Marc Carrier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-Dependent Kinase Inhibitor–Associated Thromboembolism
- (2018) Sven R. Olson et al. JAMA Oncology
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of CDK4/6 Inhibition in Breast Cancer
- (2015) C. G. Murphy et al. ONCOLOGIST
- Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States
- (2012) Alok A. Khorana et al. CANCER
- Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
- (2010) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a predictive model for chemotherapy-associated thrombosis
- (2008) A. A. Khorana et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started